Magnesium Sulfate — Competitive Intelligence Brief

Magnesium Sulfate (Magnesium Sulfate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Electrolyte; anticonvulsant.

marketed Electrolyte; anticonvulsant Neuromuscular junction; motor nerve impulse; acetylcholine release Small molecule

Target snapshot

Magnesium Sulfate — Pfizer. Magnesium blocks neuromuscular transmission and decreases acetylcholine release, preventing seizures in preeclampsia and eclampsia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Magnesium Sulfate TARGET	Magnesium Sulfate	Pfizer	marketed	Electrolyte; anticonvulsant	Neuromuscular junction; motor nerve impulse; acetylcholine release	1981-01-01
Potassium Phosphates	Potassium Phosphate, Dibasic	Pfizer	marketed	Electrolyte replacement	Phosphorus homeostasis and cellular biochemical functions	1993-01-01
Plegisol In Plastic Container	Calcium Chloride	Pfizer	marketed	Electrolyte replacement solution	Electrolyte balance and fluid homeostasis	1971-01-01
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Mg Cl	Mg Cl	University of Vermont	marketed	Electrolyte supplement / mineral replacement
Magnesium Sulfate Infusion	Magnesium Sulfate Infusion	Ondokuz Mayıs University	marketed	Electrolyte supplement / anticonvulsant / tocolytic agent	NMDA receptor antagonist; calcium channel modulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Electrolyte; anticonvulsant class)

1. Pfizer · 1 drug in this class